Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259431 | 1.00 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL14145063 | 0.89 | ADORA3 (0.71) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL14947688 | 0.89 | ADORA3 (0.71) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL22616893 | 0.89 | ADORA3 (0.71) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL14401012 | 0.89 | ADORA3 (0.71) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL18172260 | 0.87 | ADORA3 (0.73) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2113158 | 0.87 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL5733877 | 0.87 | ADORA2A (0.81) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL5733892 | 0.87 | ADORA2A (0.81) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL8933304 | 0.87 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112714649-A | Novel cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2021-04-27 | — | — | CN | disclosed |
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1802316-B1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7863253-B2 | Purine Derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1996020-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007111954-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHAMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1802316-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2006-06-15 | — | — | US | disclosed |
| WO-2006034190-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| US-5013829-A | Stable congener of 2',3'-dideoxyadenosine | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | ADORA2A 314/4885ADORA3 342/4885ADORA1 364/4885 |
| US-20070238694-A1 | Purine compounds and methods of use thereof | PNP, ADORA2A, P2RY1 | ADORA2A 2/4885ADORA3 28/4885ADORA1 9/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | ADORA2A 231/4885ADORA3 255/4885ADORA1 287/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | ADORA2A 231/4885ADORA3 255/4885ADORA1 287/4885 |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | ADORA2A 4/4885ADORA3 26/4885ADORA1 22/4885 |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | PNP, NUDT1, HPRT1 | ADORA2A 4/4885ADORA3 26/4885ADORA1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.